Vitrolife postpones the Annual General Meeting
Due to the great uncertainty caused by the extensive dissemination of covid-19, Vitrolife's Board of Directors has decided to postpone the Annual General Meeting to a later date.
The Annual General Meeting was originally scheduled to be held on April 28, 2020 in Gothenburg. Vitrolife will return with a notice to the AGM no later than four weeks before the new date. The meeting will be held in accordance with current legislation.
April 2, 2020
VITROLIFE AB (publ)
Queries should be addressed to:
Mikael Engblom, CFO, tel 46 31 721 80 14
The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on April 2, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.
Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: email@example.com. Website: www.vitrolife.com/